Klotho Neurosciences (KLTO) Stock Analysis

What Klotho Neurosciences does

Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.

Key metrics

ETFs linked to KLTO

Broad-market and Healthcare sector ETFs an investor holding Klotho Neurosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KLTO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Klotho Neurosciences?

Klotho Neurosciences trades under the ticker KLTO on NASDAQ.

Which exchange is KLTO listed on?

KLTO is listed on NASDAQ.

What sector does Klotho Neurosciences operate in?

Klotho Neurosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KLTO in a portfolio?

PortView shows KLTO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.